Spark Therapeutics, Inc. (NASDAQ:ONCE) received a $89.00 target price from research analysts at BMO Capital Markets in a report issued on Tuesday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. BMO Capital Markets’ price target suggests a potential upside of 2.61% from the stock’s previous close.

Other analysts also recently issued research reports about the stock. Chardan Capital raised shares of Spark Therapeutics from a “neutral” rating to a “buy” rating and increased their target price for the stock from $60.00 to $100.00 in a research report on Wednesday, August 2nd. Jefferies Group LLC initiated coverage on shares of Spark Therapeutics in a research report on Monday, July 10th. They set a “buy” rating and a $85.00 target price for the company. Cantor Fitzgerald set a $94.00 target price on shares of Spark Therapeutics and gave the stock a “buy” rating in a research report on Monday, July 17th. UBS AG reissued a “buy” rating and set a $92.00 target price (up previously from $70.00) on shares of Spark Therapeutics in a research report on Thursday, August 3rd. Finally, Stifel Nicolaus reissued a “buy” rating and set a $92.00 target price (up previously from $77.00) on shares of Spark Therapeutics in a research report on Thursday, August 3rd. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and seventeen have assigned a buy rating to the stock. Spark Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $88.38.

Spark Therapeutics (NASDAQ:ONCE) opened at 86.74 on Tuesday. The stock has a 50 day moving average of $85.90 and a 200 day moving average of $85.90. Spark Therapeutics has a 1-year low of $35.07 and a 1-year high of $91.00. The stock’s market cap is $2.71 billion.

Spark Therapeutics (NASDAQ:ONCE) last posted its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.75) by ($0.14). The business had revenue of $1.48 million for the quarter, compared to analyst estimates of $1.33 million. Spark Therapeutics had a negative return on equity of 59.74% and a negative net margin of 962.72%. The firm’s revenue for the quarter was up 14.7% compared to the same quarter last year. During the same period last year, the company posted ($1.04) EPS. Equities analysts expect that Spark Therapeutics will post ($7.67) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Spark Therapeutics, Inc. (ONCE) PT Set at $89.00 by BMO Capital Markets” was originally reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/10/11/spark-therapeutics-inc-once-pt-set-at-89-00-by-bmo-capital-markets.html.

In other news, Director Anand Mehra sold 211,858 shares of the stock in a transaction that occurred on Monday, July 24th. The stock was sold at an average price of $70.15, for a total transaction of $14,861,838.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Daniel Faga sold 1,500 shares of the stock in a transaction that occurred on Tuesday, September 19th. The shares were sold at an average price of $85.00, for a total value of $127,500.00. Following the transaction, the insider now owns 1,500 shares of the company’s stock, valued at $127,500. The disclosure for this sale can be found here. Insiders sold 1,333,195 shares of company stock valued at $109,070,506 in the last ninety days. 7.30% of the stock is owned by corporate insiders.

Several institutional investors have recently added to or reduced their stakes in ONCE. BlackRock Inc. boosted its stake in shares of Spark Therapeutics by 11,332.0% during the 1st quarter. BlackRock Inc. now owns 1,840,214 shares of the biotechnology company’s stock valued at $98,158,000 after buying an additional 1,824,117 shares during the last quarter. Baker BROS. Advisors LP purchased a new position in shares of Spark Therapeutics during the 3rd quarter valued at approximately $79,180,000. JPMorgan Chase & Co. boosted its stake in shares of Spark Therapeutics by 98.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,349,580 shares of the biotechnology company’s stock valued at $69,003,000 after buying an additional 670,360 shares during the last quarter. Janus Henderson Group PLC purchased a new position in shares of Spark Therapeutics during the 2nd quarter valued at approximately $30,848,000. Finally, Victory Capital Management Inc. purchased a new position in shares of Spark Therapeutics during the 3rd quarter valued at approximately $28,290,000. Institutional investors own 77.84% of the company’s stock.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.